Oleg Gladkov
About
Oleg Gladkov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Oleg Gladkov has authored 65 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Oleg Gladkov's work include Cancer Treatment and Pharmacology (14 papers), Neutropenia and Cancer Infections (14 papers) and Lung Cancer Treatments and Mutations (14 papers). Oleg Gladkov is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Neutropenia and Cancer Infections (14 papers) and Lung Cancer Treatments and Mutations (14 papers). Oleg Gladkov collaborates with scholars based in Russia, United States and Ukraine. Oleg Gladkov's co-authors include Robert E. Hawkins, Carlos H. Barrios, Pamela Salman, Lauren McCann, Jozef Mardiak, John Wagstaff, Cora N. Sternberg, Cezary Szczylik, Eunsik Lee and Juan José Zarbá and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Oleg Gladkov
58 papers receiving 3.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oleg Gladkov Russia | 18 | 2.3k | 1.8k | 1.8k | 1.1k | 285 | 65 | 3.7k | ||
| N. Moore Switzerland | 16 | 2.6k 1.1× | 1.7k 1.0× | 2.0k 1.1× | 1.2k 1.1× | 266 0.9× | 27 | 4.0k | ||
| Erhan Gökmen Türkiye | 12 | 2.2k 1.0× | 2.1k 1.1× | 1.0k 0.6× | 1.3k 1.2× | 264 0.9× | 56 | 3.4k | ||
| Janice Dutcher United States | 9 | 2.6k 1.1× | 2.4k 1.3× | 1.1k 0.6× | 1.4k 1.2× | 276 1.0× | 13 | 3.6k | ||
| Ana M. Molina United States | 30 | 2.5k 1.1× | 1.7k 0.9× | 1.2k 0.7× | 1.2k 1.1× | 368 1.3× | 129 | 3.5k | ||
| Marine Gross‐Goupil France | 29 | 1.9k 0.8× | 995 0.5× | 1.4k 0.8× | 664 0.6× | 532 1.9× | 175 | 2.9k | ||
| Benoit Beuselinck Belgium | 28 | 2.2k 0.9× | 1.4k 0.8× | 1.3k 0.7× | 917 0.8× | 455 1.6× | 164 | 2.9k | ||
| Gladys Urbanowitz United States | 8 | 2.2k 0.9× | 1.9k 1.1× | 2.0k 1.1× | 996 0.9× | 575 2.0× | 12 | 4.2k | ||
| Pamela Salman Chile | 11 | 2.7k 1.2× | 1.6k 0.9× | 1.5k 0.8× | 1.1k 0.9× | 495 1.7× | 22 | 3.4k | ||
| Norbert Hollaender Switzerland | 15 | 2.5k 1.1× | 2.4k 1.3× | 1.0k 0.6× | 1.3k 1.2× | 295 1.0× | 29 | 4.0k | ||
| Neeraj Agarwal United States | 34 | 3.4k 1.4× | 1.9k 1.0× | 1.6k 0.9× | 1.4k 1.3× | 1.1k 3.9× | 207 | 4.8k |
Countries citing papers authored by Oleg Gladkov
Since
Specialization
Citations
This map shows the geographic impact of Oleg Gladkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oleg Gladkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oleg Gladkov more than expected).
Fields of papers citing papers by Oleg Gladkov
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Oleg Gladkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oleg Gladkov. The network helps show where Oleg Gladkov may publish in the future.
Co-authorship network of co-authors of Oleg Gladkov
This figure shows the co-authorship network connecting the top 25 collaborators of Oleg Gladkov. A scholar is included among the top collaborators of Oleg Gladkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oleg Gladkov. Oleg Gladkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gladkov, Oleg, et al.. (2023). Nutritional support for patients with malignant tumors. 24(3). 264–272.
2.
Fedyanin, М. Yu., et al.. (2021). Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study. SHILAP Revista de lepidopterología. 11(1). 11–20.
3.
Sezer, Ahmet, Saadettin Kılıçkap, Mahmut Gümüş, et al.. (2020). LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Annals of Oncology. 31. S1182–S1183.
4.
Sezer, Ahmet, Miranda Gogishvili, Dmitry Bentsion, et al.. (2019). P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%. Journal of Thoracic Oncology. 14(10). S638–S638.
5.
Sriuranpong, Virote, Özden Altundağ, P. Clingan, et al.. (2018). EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. Annals of Oncology. 29. x37–x38.
6.
Hawkins, Robert E., Martin Gore, Yaroslav Shparyk, et al.. (2016). A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clinical Cancer Research. 22(13). 3172–3181.
7.
Hingorani, Sunil R., William Proctor Harris, J. Thaddeus Beck, et al.. (2016). Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research. 22(12). 2848–2854.
8.
Volovăț, Constantin, Igor Bondarenko, Oleg Gladkov, et al.. (2016). Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Supportive Care in Cancer. 24(12). 4913–4920.
9.
LaBonte, Melissa J., Dongyun Yang, Wu Zhang, et al.. (2016). A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Molecular Cancer Therapeutics. 15(9). 2251–2258.
10.
Gladkov, Oleg, et al.. (2015). Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Supportive Care in Cancer. 24(1). 395–400.
11.
Volovăț, Constantin, Igor Bondarenko, Oleg Gladkov, et al.. (2015). Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. SpringerPlus. 4(1). 316–316.
12.
Gladkov, Oleg, Vladimir Moiseyenko, Igor Bondarenko, et al.. (2015). Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Medical Oncology. 32(6). 623–623.
13.
Gladkov, Oleg, Rodryg Ramlau, Piotr Serwatowski, et al.. (2015). Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer. Anti-Cancer Drugs. 26(10). 1061–1068.
14.
Tabernero, Josep, Rocio García‐Carbonero, James T. Cassidy, et al.. (2013). Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research. 19(9). 2541–2550.
15.
Volovăț, Constantin, Oleg Gladkov, Igor Bondarenko, et al.. (2013). Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. Clinical Breast Cancer. 14(2). 101–108.
16.
Sternberg, Cora N., Robert E. Hawkins, John Wagstaff, et al.. (2013). A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer. 49(6). 1287–1296.
17.
Cristofanilli, Massimo, Stephen Johnston, Alexey Manikhas, et al.. (2012). A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Research and Treatment. 137(2). 471–482.
18.
Cristofanilli, Massimo, Stephen Johnston, Alexey Manikhas, et al.. (2012). A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).. Journal of Clinical Oncology. 30(15_suppl). 531–531.
19.
Poddubnaya, I V, Mikhail Lichinitser, Л. В. Болотина, et al.. (2011). Klinicheskie rekomendatsii po profilaktikei lecheniyu toshnoty i rvoty u bol'nykh,poluchayushchikh khimio- i luchevuyuprotivoopukholevuyu terapiyu. SHILAP Revista de lepidopterología.
20.
Sternberg, Cora N., Ian D. Davis, Jozef Mardiak, et al.. (2010). Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 28(6). 1061–1068.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by N. Moore Breakdown of academic impact, for papers by Erhan Gökmen Breakdown of academic impact, for papers by Janice Dutcher Breakdown of academic impact, for papers by Ana M. Molina Breakdown of academic impact, for papers by Marine Gross‐Goupil Breakdown of academic impact, for papers by Benoit Beuselinck Breakdown of academic impact, for papers by Gladys Urbanowitz Breakdown of academic impact, for papers by Pamela Salman Breakdown of academic impact, for papers by Norbert Hollaender Breakdown of academic impact, for papers by Neeraj Agarwal